Поиск

Автор

Ключевое слово

Коллекция

Дополнительно:

Период публикации

Научный руководитель

Оппонент

По вашему запросу найдено документов: 29

Страница 1 из 3

Герминальные мутации как возможные биомаркеры эффективности терапии ингибиторами контрольных точек иммунитета у пациентов с почечно-клеточной карциномой (мини-обзор)

Germline mutations as possible biomarkers of immune checkpoint inhibitor therapy efficacy in patients with renal cell carcinoma (mini review)

Germline mutations as possible biomarkers of immune checkpoint inhibitor therapy efficacy

Prospects for the treatment of neurofibromatosis type 1: A review

Mustafin, R.N., Мустафин, Р.Н. (2022)

of 1:3000 in human population. About 50% of NF1 cases are sporadic due to newly emerging germline

Перспективы PARP-ингибиторов при лечении BRCA-ассоциированного рака поджелудочной железы. Обзор литературы

Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review

К. В. Меньшиков, K. V. Menshikov, А. В. Султанбаев, A. V. Sultanbaev, Ш. И. Мусин, Sh. I. Musin, А. А. Измайлов, A. A. Izmailov, И. А. Меньшиков, I. A. Menshikova, Н. И. Султанбаева, N. I. Sultanbaeva, Е. В. Попова, E. V. Popova, Л. А. Хамматова, L. A. Khammatova (Креативная хирургия и онкология, №1, 2022)

Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review

Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа

Immune system changes in the pathogenesis of neurofibromatosis type 1

Mustafin, R.N., Мустафин, Р.Н. (2022)

of the population. NF1 is caused by germline heterozygous mutations in the NF1 gene, which encodes

Перспективы применения статинов в лечении нейрофиброматоза 1-го типа

Prospects for the use of statins in the treatment of neurofibromatosis type 1

Mustafin, R.N., Мустафин, Р.Н. (2022)

Вероятная роль ретроэлементов в развитии опухоли Вильмса при хромосомных синдромах

The probable role of retroelements in the development of Wilms' tumor in chromosomal syndromes

Мустафин, Р.Н., Mustafin, R.N. (2022)

Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma

Bai, Ming, Wang, Xiaolong, Zhang, Huixue, Wang, Jianjian, Lyaysan, Gaysina, Xu, Si, Tian, Kuo, Wang, Tianfeng, Li, Jie, Wang, Na, Lu, Xiaoyu, Zhang, Xiaoming, Wang, Lihua (2022)

, we first performed an integrative framework to infer the clonal status of mutations in glioblastomas

Analysis of ATL1 Gene Mutations and Clinical Features of the Disease Course in Patients with Hereditary Spastic Paraplegia

Khidiyatova, I.M., Saifullina, E.V., Karunas, A.S., Akhmetgaleyeva, A.F., Kutlubaeva, R.F., Smakova, L.A., Lobov, S.L., Polyakov, A.V., Shchagina, O.A., Kadnikova, V.A., Ryzhkova, O.P., Magzhanov, R.V. (2022)

predominant lesion of the pyramidal tract. The autosomal dominant form of SPG3A, associated with mutations

Does the c.-14C>T Mutation in the IFITM5 Gene Provide Identical Phenotypes for Osteogenesis Imperfecta Type V? Data from Russia and a Literature Review

Tyurin, Anton, Merkuryeva, Elena, Zaripova, Aliya, Markova, Tatyana, Nagornova, Tatyana, Dantsev, Ilya, Nadyrshina, Dina, Zakharova, Ekaterina, Khusainova, Rita (2022)

shown that a mutation (c.-14C>T) in the IFITM5 gene is responsible for autosomal dominant OI type V

Osteogenesis Imperfecta: Search for Mutations in Patients from the Republic of Bashkortostan (Russia)

Nadyrshina, D., Zaripova, A., Tyurin, A., Minniakhmetov, I., Zakharova, E., Khusainova, R. (2022)

in patients from Bashkortostan Republic, Russia. In total, 16 mutations in COL1A1, 11 mutations in COL1A2

Страница 1 из 3